Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer
- PMID: 27586145
- DOI: 10.1007/s12032-016-0819-8
Association between polymorphisms in xenobiotic detoxification-related genes with prognosis of epithelial ovarian cancer
Abstract
This study aimed to evaluate whether GSTM1 and GSTT1 (presents or nulls), GSTP1 c.313A>G and NQO2 c.-102A>C polymorphisms, involved in xenobiotic detoxification pathways, alter outcomes of epithelial ovarian cancer (EOC) patients. DNA from 84 EOC patients diagnosed at the University of Campinas Academic Hospital from January 1995 and July 2007 was analyzed by polymerase chain reaction and restriction fragment length polymorphism assays. The prognostic impact of genotypes of polymorphisms on progression-free survival and overall survival (OS) of EOC patients was examined using the Kaplan-Meier probability estimates and univariate and multivariate Cox proportional hazard ratio (HR) regression analyses. The significant results of Cox analyses were validated using a bootstrap resampling study (1000 replications). At 60 months of follow-up, lower OS was seen in patients with GSTT1 null genotype (50.0 vs. 76.7 %, P = 0.02) compared with the other genotype (Kaplan-Meier estimate). This outcome remained the same in univariate Cox analysis (HR 2.22, P = 0.02). After multivariate Cox analysis, patients with GSTT1 null (HR 2.11, P = 0.04, P bootstrap = 0.04) and NQO2 AA (HR 2.13, P = 0.03, P bootstrap = 0.04) genotypes were under greater risks of progressing to death when compared with those with others genotypes. Our data suggest, for the first time, that inherited abnormalities in xenobiotic detoxification pathway related to GSTT1 and NQO2 c.-102A>C polymorphisms act as independent prognostic factors for OS of EOC patients.
Keywords: Epithelial ovarian cancer; GSTT1; NQO2; Prognosis; Single nucleotide polymorphism.
Similar articles
-
Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future.Genes (Basel). 2024 Jan 10;15(1):87. doi: 10.3390/genes15010087. Genes (Basel). 2024. PMID: 38254976 Free PMC article. Review.
-
Polymorphisms of glutathione S-transferase Mu 1 (GSTM1), Theta 1 (GSTT1), and Pi 1 (GSTP1) genes and epithelial ovarian cancer risk.Dis Markers. 2012;33(3):155-9. doi: 10.1155/2012/497692. Dis Markers. 2012. PMID: 22960333 Free PMC article.
-
Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.Gynecol Oncol. 2013 Mar;128(3):584-9. doi: 10.1016/j.ygyno.2012.12.002. Epub 2012 Dec 9. Gynecol Oncol. 2013. PMID: 23234803
-
Polymorphic expression of glutathione transferases A1, M1, P1 and T1 in epithelial ovarian cancer: a Serbian case-control study.J BUON. 2017 Jan-Feb;22(1):72-79. J BUON. 2017. PMID: 28365938
-
Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies.Gynecol Oncol. 2013 Jun;129(3):613-9. doi: 10.1016/j.ygyno.2013.02.011. Epub 2013 Feb 17. Gynecol Oncol. 2013. PMID: 23422504 Review.
Cited by
-
Polymorphisms and Pharmacogenomics of NQO2: The Past and the Future.Genes (Basel). 2024 Jan 10;15(1):87. doi: 10.3390/genes15010087. Genes (Basel). 2024. PMID: 38254976 Free PMC article. Review.
-
GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.Oncotarget. 2018 Jul 3;9(51):29789-29800. doi: 10.18632/oncotarget.25712. eCollection 2018 Jul 3. Oncotarget. 2018. PMID: 30038720 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous